Immuron (IMRN) Long-Term Investments (2022 - 2023)
Immuron (IMRN) posted quarterly Long-Term Investments of $1590.7 for Q4 2023, down 27.9% year-on-year from $2206.1 in Q4 2022, and down 98.58% on a QoQ basis from $112336.3 in Q3 2023.
Immuron (IMRN) Long-Term Investments (2022 - 2023) Analysis & Trends
Immuron (IMRN) has reported Long-Term Investments for 2 consecutive years, with $1590.7 the latest figure, recorded in Q4 2023.
- Quarterly Long-Term Investments fell 27.9% year-over-year to $1590.7 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1590.7 (down 27.9% YoY) and the FY2023 annual result came in at $1590.7, down 27.9% from the prior year.
- Long-Term Investments slipped to $1590.7 in Q4 2023 per IMRN's latest filing, from $112336.3 in the prior quarter.
- Over the last five years, Long-Term Investments for IMRN reached as high as $159066.0 in Q2 2023 and fell as low as $1590.7 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 505,194.89 |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 9.79 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1,590.66 |
| Sep 28, 2023 | 112,336.33 |
| Aug 30, 2023 | 1,590.66 |
| Jun 30, 2023 | 159,066.00 |
| Dec 31, 2022 | 2,206.11 |